Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Director | June 09, 2026 | June 11, 2026 |
| Telesis Bio Inc.TBIO · Entity 15606 | Director · 10% owner | June 05, 2023 | June 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARVARD BIOSCIENCE INC
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,556 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 16,556 · Balance 48,556 F1: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier. F2: Includes (a) the award described in footnote (1) above, (b) 12,525 shares of common stock purchased on March 16, 2026, (c) 8,475 shares of common stock purchased on March 17, 2026, and (d) 11,000 restricted stock units that fully vest on December 17, 2026. F3: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(d) were previously reported as covering 110,000 restricted stock units. This number has been adjusted to reflect the stock split that occurred on March 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
F2: Includes (a) the award described in footnote (1) above, (b) 12,525 shares of common stock purchased on March 16, 2026, (c) 8,475 shares of common stock purchased on March 17, 2026, and (d) 11,000 restricted stock units that fully vest on December 17, 2026.
F3: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(d) were previously reported as covering 110,000 restricted stock units. This number has been adjusted to reflect the stock split that occurred on March 13, 2026.
Telesis Bio Inc.
Report date June 05, 2023 · Filed June 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 | IndirectSee footnote | 20,000 |
Reported balance
After 2023-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-05 · Grant · Acquired 20,000 · Balance 20,000 F3: The Preferred Stock was sold in fixed combinations with the warrants, with BroadOak Fund IV, LLC ("BroadOak") receiving (a) a Short-Term Warrant (as defined in the Purchase Agreement) to purchase one-half of a share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak and (b) a Long-Term Warrant (as defined in the Purchase Agreement) to purchase one share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak. The purchase price per share of Preferred Stock and accompanying Short-Term Warrant and Long-Term Warrant was $100.00. F1: The Redeemable Convertible Preferred Stock, par value $0.0001 per share, (the "Preferred Stock") has no expiration date. F2: Pursuant to the Certificate of Designation contemplated by the Redeemable Convertible Preferred Stock and Warrant Purchase Agreement dated as of May 31, 2023 (the "Purchase Agreement") (the "Certificate of Designation"), each share of Preferred Stock may be converted at any time into Common Stock as is determined by dividing (i) the sum of the Accrued Value (as defined in the Certificate of Designation) plus an amount equal to all accrued or declared and unpaid dividends on the Preferred Stock that have not previously been added to the Accrued Value by (ii) the Conversion Price in effect at the time of conversion. The "Conversion Price" shall initially be equal to $2.3633 per share. The rate at which shares of Preferred Stock may be converted into shares of Common Stock shall be subject to adjustment pursuant to the Certificate of Designation. Each share of Preferred Stock is initially convertible into approximately 42.3 shares of Common Stock. F4: Preferred Stock, Short-Term Warrant and Long-Term Warrant held of record by BroadOak. BroadOak Asset Management, LLC is the manager and general partner of BroadOak, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any. |
| Short-Term WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2025-06-05 | IndirectSee footnote | 423,137 |
Reported balance
After 2023-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-05 · Grant · Acquired 423,137 · Balance 423,137 F3: The Preferred Stock was sold in fixed combinations with the warrants, with BroadOak Fund IV, LLC ("BroadOak") receiving (a) a Short-Term Warrant (as defined in the Purchase Agreement) to purchase one-half of a share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak and (b) a Long-Term Warrant (as defined in the Purchase Agreement) to purchase one share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak. The purchase price per share of Preferred Stock and accompanying Short-Term Warrant and Long-Term Warrant was $100.00. F5: BroakOak may elect to receive to receive a Pre-Funded Warrant (as defined in the Purchase Agreement) in lieu of shares of Common Stock upon exercise of the Short-Term or Long-Term Warrant. F4: Preferred Stock, Short-Term Warrant and Long-Term Warrant held of record by BroadOak. BroadOak Asset Management, LLC is the manager and general partner of BroadOak, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any. |
| Long-Term WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2030-06-05 | IndirectSee footnote | 846,274 |
Reported balance
After 2023-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-05 · Grant · Acquired 846,274 · Balance 846,274 F3: The Preferred Stock was sold in fixed combinations with the warrants, with BroadOak Fund IV, LLC ("BroadOak") receiving (a) a Short-Term Warrant (as defined in the Purchase Agreement) to purchase one-half of a share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak and (b) a Long-Term Warrant (as defined in the Purchase Agreement) to purchase one share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak. The purchase price per share of Preferred Stock and accompanying Short-Term Warrant and Long-Term Warrant was $100.00. F5: BroakOak may elect to receive to receive a Pre-Funded Warrant (as defined in the Purchase Agreement) in lieu of shares of Common Stock upon exercise of the Short-Term or Long-Term Warrant. F4: Preferred Stock, Short-Term Warrant and Long-Term Warrant held of record by BroadOak. BroadOak Asset Management, LLC is the manager and general partner of BroadOak, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The Redeemable Convertible Preferred Stock, par value $0.0001 per share, (the "Preferred Stock") has no expiration date.
F2: Pursuant to the Certificate of Designation contemplated by the Redeemable Convertible Preferred Stock and Warrant Purchase Agreement dated as of May 31, 2023 (the "Purchase Agreement") (the "Certificate of Designation"), each share of Preferred Stock may be converted at any time into Common Stock as is determined by dividing (i) the sum of the Accrued Value (as defined in the Certificate of Designation) plus an amount equal to all accrued or declared and unpaid dividends on the Preferred Stock that have not previously been added to the Accrued Value by (ii) the Conversion Price in effect at the time of conversion. The "Conversion Price" shall initially be equal to $2.3633 per share. The rate at which shares of Preferred Stock may be converted into shares of Common Stock shall be subject to adjustment pursuant to the Certificate of Designation. Each share of Preferred Stock is initially convertible into approximately 42.3 shares of Common Stock.
F3: The Preferred Stock was sold in fixed combinations with the warrants, with BroadOak Fund IV, LLC ("BroadOak") receiving (a) a Short-Term Warrant (as defined in the Purchase Agreement) to purchase one-half of a share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak and (b) a Long-Term Warrant (as defined in the Purchase Agreement) to purchase one share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak. The purchase price per share of Preferred Stock and accompanying Short-Term Warrant and Long-Term Warrant was $100.00.
F4: Preferred Stock, Short-Term Warrant and Long-Term Warrant held of record by BroadOak. BroadOak Asset Management, LLC is the manager and general partner of BroadOak, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any.
F5: BroakOak may elect to receive to receive a Pre-Funded Warrant (as defined in the Purchase Agreement) in lieu of shares of Common Stock upon exercise of the Short-Term or Long-Term Warrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 16:56 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 16,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-004060 · ownership.xml · nonDerivative · entry 1 Snider William · CIK 0001340831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,556 F1 · shares: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 12,525 shares of common stock purchased on March 16, 2026, (c) 8,475 shares of common stock purchased on March 17, 2026, and (d) 11,000 restricted stock units that fully vest on December 17, 2026. F3 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(d) were previously reported as covering 110,000 restricted stock units. This number has been adjusted to reflect the stock split that occurred on March 13, 2026. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 11:31 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 8,475 | $4.85 | $41,103.75 |
DisclosureSEC source: 0001171843-26-001689 · ownership.xml · nonDerivative · entry 2 Snider William · CIK 0001340831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 F2 · price: The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.80 to $4.95, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price. F4 · balance_after: Includes (a) 12,525 shares of common stock purchased on March 16, 2026, (b) 8,475 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on December 17, 2026. F5 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 11:31 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 12,525 | $4.99 | $62,499.75 |
DisclosureSEC source: 0001171843-26-001689 · ownership.xml · nonDerivative · entry 1 Snider William · CIK 0001340831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,525 F1 · price: The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.85 to $5.00, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the Securities and Exchange Commission ("SEC") staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price. F3 · balance_after: Includes (a) 12,525 shares of common stock purchased on March 16, 2026, and (b) 11,000 restricted stock units that fully vest on December 17, 2026. F5 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. Read SEC document |
| December 17, 2025 Filed Dec 31, 2025 01:48 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-008127 · ownership.xml · nonDerivative · entry 1 Snider William · CIK 0001340831 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 F1 · shares: Represents an award of 110,000 restricted stock units that fully vest on December 17, 2026. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 16:11 UTC | Telesis Bio Inc. TBIO · Entity 15606 | GrantLong-Term Warrant · Derivative | 846,274 | Not disclosed Strike: $2.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-035056 · doc4.xml · derivative · entry 3 Snider William · CIK 0001340831 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 846,274 Underlying: Common Stock · 846,274 shares Expires 2030-06-05 F3 · price: The Preferred Stock was sold in fixed combinations with the warrants, with BroadOak Fund IV, LLC ("BroadOak") receiving (a) a Short-Term Warrant (as defined in the Purchase Agreement) to purchase one-half of a share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak and (b) a Long-Term Warrant (as defined in the Purchase Agreement) to purchase one share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak. The purchase price per share of Preferred Stock and accompanying Short-Term Warrant and Long-Term Warrant was $100.00. F5 · derivative.underlying_shares: BroakOak may elect to receive to receive a Pre-Funded Warrant (as defined in the Purchase Agreement) in lieu of shares of Common Stock upon exercise of the Short-Term or Long-Term Warrant. F4 · ownership.nature: Preferred Stock, Short-Term Warrant and Long-Term Warrant held of record by BroadOak. BroadOak Asset Management, LLC is the manager and general partner of BroadOak, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 16:11 UTC | Telesis Bio Inc. TBIO · Entity 15606 | GrantShort-Term Warrant · Derivative | 423,137 | Not disclosed Strike: $2.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-035056 · doc4.xml · derivative · entry 2 Snider William · CIK 0001340831 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 423,137 Underlying: Common Stock · 423,137 shares Expires 2025-06-05 F3 · price: The Preferred Stock was sold in fixed combinations with the warrants, with BroadOak Fund IV, LLC ("BroadOak") receiving (a) a Short-Term Warrant (as defined in the Purchase Agreement) to purchase one-half of a share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak and (b) a Long-Term Warrant (as defined in the Purchase Agreement) to purchase one share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak. The purchase price per share of Preferred Stock and accompanying Short-Term Warrant and Long-Term Warrant was $100.00. F5 · derivative.underlying_shares: BroakOak may elect to receive to receive a Pre-Funded Warrant (as defined in the Purchase Agreement) in lieu of shares of Common Stock upon exercise of the Short-Term or Long-Term Warrant. F4 · ownership.nature: Preferred Stock, Short-Term Warrant and Long-Term Warrant held of record by BroadOak. BroadOak Asset Management, LLC is the manager and general partner of BroadOak, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 16:11 UTC | Telesis Bio Inc. TBIO · Entity 15606 | GrantRedeemable Convertible Preferred Stock · Derivative | 20,000 | Not disclosed Strike: $2.36 | Not disclosed |
DisclosureSEC source: 0001209191-23-035056 · doc4.xml · derivative · entry 1 Snider William · CIK 0001340831 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 20,000 Underlying: Common Stock · Not disclosed shares Expires not disclosed F3 · price: The Preferred Stock was sold in fixed combinations with the warrants, with BroadOak Fund IV, LLC ("BroadOak") receiving (a) a Short-Term Warrant (as defined in the Purchase Agreement) to purchase one-half of a share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak and (b) a Long-Term Warrant (as defined in the Purchase Agreement) to purchase one share of Common Stock per each share of Common Stock initially underlying the Preferred Stock purchased by BroadOak. The purchase price per share of Preferred Stock and accompanying Short-Term Warrant and Long-Term Warrant was $100.00. F1 · derivative.expiration_date: The Redeemable Convertible Preferred Stock, par value $0.0001 per share, (the "Preferred Stock") has no expiration date. F2 · derivative.underlying_shares: Pursuant to the Certificate of Designation contemplated by the Redeemable Convertible Preferred Stock and Warrant Purchase Agreement dated as of May 31, 2023 (the "Purchase Agreement") (the "Certificate of Designation"), each share of Preferred Stock may be converted at any time into Common Stock as is determined by dividing (i) the sum of the Accrued Value (as defined in the Certificate of Designation) plus an amount equal to all accrued or declared and unpaid dividends on the Preferred Stock that have not previously been added to the Accrued Value by (ii) the Conversion Price in effect at the time of conversion. The "Conversion Price" shall initially be equal to $2.3633 per share. The rate at which shares of Preferred Stock may be converted into shares of Common Stock shall be subject to adjustment pursuant to the Certificate of Designation. Each share of Preferred Stock is initially convertible into approximately 42.3 shares of Common Stock. F4 · ownership.nature: Preferred Stock, Short-Term Warrant and Long-Term Warrant held of record by BroadOak. BroadOak Asset Management, LLC is the manager and general partner of BroadOak, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 18:09 UTC | Telesis Bio Inc. DNAY · Entity 15606 | GrantStock Option (right to buy) · Derivative | 30,945 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001850079-22-000048 · wf-form4_165515815656608.xml · derivative · entry 3 Snider William · CIK 0001340831 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,945 Underlying: Common Stock · 30,945 shares Expires 2032-06-09 F3 · derivative.exercise_date: Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Sock Incentive Plan) through each such date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the Grant Date or (ii) the day prior to the date of the annual meeting of the Issuer's shareholders next following the Grant Date. "Grant Date" shall mean June 9, 2022. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 18:09 UTC | Telesis Bio Inc. DNAY · Entity 15606 | GrantCommon Stock | 20,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001850079-22-000048 · wf-form4_165515815656608.xml · nonDerivative · entry 1 Snider William · CIK 0001340831 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,630 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Codex DNA, Inc.'s (the "Issuer") Common Stock. Subject to the Reporting Person's continuing as a Service Provider (as defined in the Issuer's 2021 Sock Incentive Plan) through each such date, one hundred percent (100%) of the RSUs shall vest on the earlier of (i) the one-year anniversary of the Grant Date or (ii) the day prior to the date of the annual meeting of the Issuer's shareholders next following the Grant Date. "Grant Date" shall mean June 9, 2022. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 16:06 UTC | Telesis Bio Inc. DNAY · Entity 15606 | ConversionSeries A-1 Preferred Stock · Derivative | 277,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001850079-21-000032 · wf-form4_162447874769144.xml · derivative · entry 4 Snider William · CIK 0001340831 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 277,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F1 · price: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F2 · ownership.nature: Shares held of record by BroadOak Fund IV, LLC. BroadOak Asset Management, LLC is the manager and general partner of BroadOak Fund IV, LLC, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak Fund IV, LLC, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 16:06 UTC | Telesis Bio Inc. DNAY · Entity 15606 | ConversionSeries A Preferred Stock · Derivative | 541,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001850079-21-000032 · wf-form4_162447874769144.xml · derivative · entry 3 Snider William · CIK 0001340831 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 541,677 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F1 · price: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F2 · ownership.nature: Shares held of record by BroadOak Fund IV, LLC. BroadOak Asset Management, LLC is the manager and general partner of BroadOak Fund IV, LLC, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak Fund IV, LLC, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 16:06 UTC | Telesis Bio Inc. DNAY · Entity 15606 | ConversionSeries Z Preferred Stock · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001850079-21-000032 · wf-form4_162447874769144.xml · derivative · entry 2 Snider William · CIK 0001340831 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F1 · price: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F2 · ownership.nature: Shares held of record by BroadOak Fund IV, LLC. BroadOak Asset Management, LLC is the manager and general partner of BroadOak Fund IV, LLC, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak Fund IV, LLC, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 16:06 UTC | Telesis Bio Inc. DNAY · Entity 15606 | ConversionCommon Stock | 1,319,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001850079-21-000032 · wf-form4_162447874769144.xml · nonDerivative · entry 1 Snider William · CIK 0001340831 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,319,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date. F2 · ownership.nature: Shares held of record by BroadOak Fund IV, LLC. BroadOak Asset Management, LLC is the manager and general partner of BroadOak Fund IV, LLC, and BroadOak Capital Partners, LLC is the managing member of BroadOak Asset Management, LLC. William F. Snider is a partner and manager of BroadOak Capital Partners, LLC. Each of Mr. Snider and BroadOak Capital Partners, LLC may be deemed to have voting and dispositive power over the shares held by BroadOak Fund IV, LLC, and each disclaims beneficial ownership of such shares except to the extent of his/its indirect pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.